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 ABSTRACT  Melanoma resistant to MAPK inhibitors (MAPKi) displays loss of fi tness upon experi-
mental MAPKi withdrawal and, clinically, may be resensitized to MAPKi therapy after 
a drug holiday. Here, we uncovered and therapeutically exploited the mechanisms of MAPKi addiction 
in MAPKi-resistant  BRAF MUT or  NRAS MUT melanoma. MAPKi-addiction phenotypes evident upon drug 
withdrawal spanned transient cell-cycle slowdown to cell-death responses, the latter of which required a 
robust phosphorylated ERK (pERK) rebound. Generally, drug withdrawal–induced pERK rebound upregu-
lated p38–FRA1–JUNB–CDKN1A and downregulated proliferation, but only a robust pERK rebound 
resulted in DNA damage and parthanatos-related cell death. Importantly, pharmacologically impairing 
DNA damage repair during MAPKi withdrawal augmented MAPKi addiction across the board by convert-
ing a cell-cycle deceleration to a caspase-dependent cell-death response or by furthering parthanatos-
related cell death. Specifi cally in MEKi-resistant  NRAS MUT or atypical  BRAF MUT melanoma, treatment 
with a type I RAF inhibitor intensifi ed pERK rebound elicited by MEKi withdrawal, thereby promoting a 
cell death–predominant MAPKi-addiction phenotype. Thus, MAPKi discontinuation upon disease pro-
gression should be coupled with specifi c strategies that augment MAPKi addiction. 
 SIGNIFICANCE: Discontinuing targeted therapy may select against drug-resistant tumor clones, but 
drug-addiction mechanisms are ill-defi ned. Using melanoma resistant to but withdrawn from MAPKi, 
we defi ned a synthetic lethality between supraphysiologic levels of pERK and DNA damage. Actively 
promoting this synthetic lethality could rationalize sequential/rotational regimens that address evolv-
ing vulnerabilities.  Cancer Discov; 8(1); 74–93. ©2017 AACR. 
See related commentary by Stern, p. 20. 
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INTRODUCTION
The combination of BRAF inhibitors plus MEK inhibi-
tors (BRAFi + MEKi) extends the survival benefits of BRAFi 
monotherapy in BRAF V600-mutant melanoma by counteract-
ing MAPK-reactivating resistance mechanisms (1–9). However, 
acquired resistance to BRAFi + MEKi is the norm rather than 
the exception. In cell line and patient-derived xenograft (PDX) 
models of BRAFV600-mutant melanoma adapted to BRAFi mon-
otherapy, loss-of-fitness due to BRAFi withdrawal in a process 
termed drug addiction has been documented (2, 10). Moreover, 
the magnitude of drug addiction increases with adaptation to 
BRAFi + MEKi (2). Regardless of the extent of drug addiction, 
rebound phosphorylated ERK (pERK) levels induced by MAPKi 
(BRAFi or BRAFi + MEKi) withdrawal seemed critical for this 
phenotype, because a low dose of ERK inhibitor (ERKi) was 
sufficient to block this pERK rebound and reversed drug addic-
tion (2). However, how pERK rebound mediates tumor cell 
cycle decele ration and/or cell death is unknown. Identifying the 
factor(s) that, together with pERK rebound, incite tumor cell 
death or regression (rather than mere tumor stabilization or tran-
sient tumor cytostasis) may inform potential clinical strategies.
Anecdotal case series of patients with advanced BRAFV600- 
mutant melanoma suggest that rechallenge with a MAPKi, 
after evidence of disease progression and a brief drug holi-
day, can lead to clinical benefits, including objective tumor 
regression and enhanced life quality (11–16). More recently, 
a prospective clinical trial demonstrated that, following an 
interval of at least 12 weeks since disease progression and 
off MAPKi, rechallenge with BRAFi + MEKi led to 32% par-
tial responses and 40% disease stabilization (17). Thus, an 
intentional drug holiday may select against MAPKi-resistant 
melanoma, leading to a resensitization phenomenon. Maxi-
mizing this counter-selection may lead to greater rates of 
resensitization and, if applied against microscopic resistance 
earlier during MAPKi therapy, could lead to longer durations 
of response or disease control.
Currently, MAPKi therapy is clinically approved only for 
patients with advanced BRAFV600-mutant melanoma. This is 
because type I RAF inhibitors (vemurafenib and dabrafenib) 
specifically inhibit monomeric BRAFV600 mutants (18) but 
paradoxically activate the MAPK pathway in NRAS-mutant 
and/or dimeric RAF-active melanoma (19–22). MEKi mono-
therapy has clear clinical activity against advanced BRAFV600- 
mutant melanoma (23) but more limited activity against 
advanced NRASMUT melanoma (24). Thus, strategies against 
MEKi-resistant melanoma, including NRASMUT melanoma 
specifically and other subsets of melanoma with potential 
MAPKi sensitivity, may have clinical utility.
In this study, we sought to understand the basis of variable 
cellular responses (cell cycle versus death) to drug withdrawal 
in MAPKi-resistant melanoma. We also provided in vivo (PDX 
and murine melanoma in immune competent mice) proof-of-
concept evidence that specific therapeutic approaches could 
potentially augment MAPKi addiction by favoring tumor cell 
death over transient cell-cycle suppression. Using three inde-
pendent MEKi-resistant melanoma models with NRASMUT 
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or  atypical BRAF mutations, we derived data suggesting that 
MAPKi addiction is not exclusive to BRAFV600-mutant mela-
noma and may be a hallmark of MAPKi-resistant melanoma.
RESULTS
Depth of Drug Addiction in Resistant Melanoma 
Is Determined by Slow-Cycling versus Cell-Death 
Responses to MAPKi Withdrawal
Previously, we have shown that acquired MAPKi resistance 
mechanisms vary in their degrees of ERK reactivation (1, 3, 
25) and that the levels of MAPKi addiction correlate with 
the degrees of pERK rebound upon drug(s) withdrawal (2). 
To assess the spectrum of variations in the MAPKi-addiction 
phenotype, we analyzed the cellular responses of BRAFV600- 
mutant, double-drug resistant (DDR) melanoma cell lines 
to BRAFi + MEKi withdrawal. We extended our analysis to 
NRASQ61-mutant melanoma sublines with acquired MEKi 
resistance [M207 and M245 single-drug resistant (SDR)]. 
All 10 melanoma cell lines with diverse mechanisms (Sup-
plementary Fig. S1A) of acquired MAPKi resistance (R-lines) 
displayed MAPKi addiction (Fig. 1A). This loss-of-fitness 
response (to MAPKi withdrawal) was transient in some R-lines 
but persistent in others, suggesting reversible slow-cycling 
and (by definition, irreversible) cell-death responses, respec-
tively (Fig. 1A). By vital imaging (Fig. 1B), we observed that 
Figure 1.  MAPKi-resistant melanomas display distinct drug-addiction phenotypes characterized by slow-cycling versus cell-death responses. A, Clono-
genic growth of double-drug resistant or DDR (BRAFMUT) or single-drug resistant or SDR (NRASMUT) melanoma cell lines plated 24 hours with BRAFi (vemu-
rafenib) + MEKi (selumetinib) at 1 μmol/L or MEKi (trametinib) at 0.1 μmol/L followed by 7 days with (on) or 7 and 18 days without (off) inhibitor. B, Temporal 
vital images of MAPKi-resistant or R-lines on or off BRAFi + MEKi. C–E, Percentages of Annexin-V/PI-positive dead cells (C), CFSE dye dilution patterns (D), 
and levels of SA-βgal staining (E) in R-lines on or off MAPKi(s) for 6 days. Loading control (D) refers to the intensity of the CFSE dye initially loaded into the 
cells. F, Correlation between fold changes (FC) in CFSE dye dilution and % cell death off vs. on MAPKi(s). PI, propidium iodide.
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a subset of R-lines responded to MAPKi withdrawal by slow-
ing down proliferation, whereas a distinct subset responded 
predominantly by cell death (Fig. 1C). Consistently, cell-
cycle slowdown predominant R-lines off-MAPKi displayed 
relatively lower CFSE dye dilution compared with on-MAPKi 
(Fig. 1D). On the other hand, residual cells that escaped a pre-
dominantly cell-death response to drug withdrawal tended to 
retain dye strongly relative to the same R-lines on-MAPKi and 
the slow-cycling R-lines off-MAPKi (Fig. 1D). Furthermore, 
greater fractions of persisting cells after MAPKi withdrawal 
displayed senescence-associated β-galactosidase staining in 
the cell death–predominant R-lines (Fig. 1E), consistent with 
a reduced proliferative potential. Thus, a cell death–predomi-
nant drug-addiction phenotype characterizes MAPKi-resist-
ant melanoma cells that, upon drug withdrawal, undergo cell 
death in the majority subpopulation and a robust and per-
sistent cell-cycle deceleration in the minority, remainder sub-
population. On the other hand, a slow cycling–predominant 
drug-addiction phenotype characterizes MAPKi- resistant 
melanoma cells that, upon drug withdrawal, undergo a tran-
sient cell-cycle deceleration (Fig. 1F).
Extent of ERK Rebound Induced by MAPKi 
Withdrawal Dictates Tumor Cell Slow-Cycling or 
Death Responses
We then assessed whether the extent of MAPKi withdrawal–
induced pERK rebound (fold change from baseline) is causally 
related to distinct phenotypic outcomes. Cell death–predomi-
nant R-lines displayed greater pERK rebound when compared 
with the slow cycling–predominant R-lines (Supplementary Fig. 
S1B and S1C). Moreover, a suboptimal or low dose of an ERKi 
(Supplementary Fig. S1D), when added to cell death–predomi-
nant R-lines concomitant with MAPKi withdrawal, completely 
blocked cell death (Supplementary Fig. S1E) and, when added 
to both groups of R-lines during MAPKi withdrawal, reversed 
cell-cycle deceleration (Supplementary Fig. S1F). Consistently, 
suboptimal ERKi protected all R-lines from clonogenic growth 
suppression spurred by BRAFi +MEKi (in BRAFMUT R-lines) or 
MEKi (in NRASMUT R-lines) withdrawal (Supplementary Fig. 
S1G). We then tested whether augmenting MAPKi withdrawal–
induced pERK rebound in a slow cycling–predominant R-line 
would enhance MAPKi addiction. BRAFV600E amplification drives 
acquired MAPKi resistance via ERK reactivation (6) and has 
been associated with BRAFi (10) or BRAFi + MEKi (2) addiction. 
We engineered exogenous BRAFV600E overexpression in the slow 
cycling–predominant R-lines SKMEL28 DDR1 (Supplementary 
Fig. S1H), which increased pERK levels on and especially off 
double-drug treatment. Functionally, BRAFV600E overexpression, 
upon double-drug withdrawal, enhanced cell-death and cell-cycle 
deceleration, and suppressed long- and short-term growth (Sup-
plementary Fig. S1I–S1L). Hence, the extent of pERK rebound 
upon MAPKi withdrawal determines the addiction phenotype of 
MAPKi-resistant melanoma (Supplementary Fig. S1M).
Effectors of Cell-Cycle or Death Responses to 
MAPKi Withdrawal in Resistant Melanoma
To identify the effectors of distinct MAPKi-addiction phe-
notypes in drug-resistant melanoma, we generated RNA-
sequencing (RNA-seq) profiles of cell death–predominant 
(M249 DDR5) and slow cycling–predominant (SKMEL28 
DDR1) R-lines on (6 hours) or off (6 hours and 24 hours) 
BRAFi + MEKi. From genes that were induced ≥2 fold by 
double-drug withdrawal in both R-lines and at both time 
points (Supplementary Fig. S2A), we analyzed for transcrip-
tion factor (TF)–binding motif enrichment of the differen-
tially up-expressed genes (Supplementary Fig. S2B). Among 
the six TFs whose binding motifs were enriched, four (JUNB, 
FOSL1/FRA1, FOSL2, and c-JUN) belonged to the AP1 fam-
ily. Among these, JUNB and FOSL1/FRA1 transcripts were 
induced by MAPKi withdrawal (Supplementary Fig. S2C). 
At the protein level, both total FRA1 (and pFRA1) and total 
JUNB were induced by MAPKi withdrawal, together with 
induction of total FOS (and pFOS), FOSB, and p-p38, the 
upstream kinase (Supplementary Fig. S2D and see below). 
In slow cycling–predominant R-lines, double-drug with-
drawal induced levels of pFRA1, p-p38, and the cell-cycle 
inhibitor p21 (Supplementary Fig. S2E). Treatment with 
a p38 inhibitor (p38i) during MAPKi withdrawal reduced 
the phosphorylation of its substrate (pHSP27) but not the 
level of p21. However, treatment with p38i in combination 
with FRA1 knockdown during MAPKi withdrawal abolished 
p21 induction, accelerated cell cycling, and reversed 40% to 
60% of growth inhibition induced by MAPKi withdrawal 
in these slow cycling–predominant R-lines (Supplementary 
Fig. S2E–S2H). Given that JUNB was induced by MAPKi 
withdrawal (Supplementary Fig. S2C and S2I), we knocked 
down JUNB. Interestingly, joint JUNB and FRA1 knockdown 
abolished p21 induction by MAPKi withdrawal and recov-
ered the growth of slow cycling–predominant R-lines after 
double-drug withdrawal (Supplementary Fig. S2I and S2J). 
However, shFRA1 transduction together with p38i treatment 
in a cell death–predominant R-line, M249 DDR5, blunted 
MAPKi withdrawal–induced p21 but failed to alter the cell-
cycling profile, likely because the major growth inhibition 
phenotype, i.e., cell death, was not affected (Supplementary 
Fig. S2K–S2M). Consistently, M249 DDR5 was still strongly 
addicted to BRAFi + MEKi despite FRA1 knockdown and 
p38 inhibition (Supplementary Fig. S2N). Thus, p38–FRA1/
JUNB signaling and p21 accumulation induced by MAPKi 
withdrawal are necessary for the slow cycling but not the cell 
death–predominant phenotype of drug addiction.
To identify processes that drive the cell death–predomi-
nant MAPKi-addiction phenotype, we analyzed the RNA-seq 
data for differential gene set enrichment between SKMEL28 
DDR1 and M249 DDR5 [using the C2 (CGP subset), C6, and 
hallmark gene sets in MSigDB version 5.1] under each condi-
tion (on drug for 6 hours, off drug for 6 hours, off drug for 
24 hours). We selected gene sets that showed higher (median 
log2 difference of 1.25-fold or 25% up-expression across all 
genes in the set) gene set enrichment in one R-line compared 
with the other in either the 6 hours or 24 hours off drug 
condition, provided that this differential enrichment was 
higher (by 25%) than that observed in the baseline (on drug 
for 6 hours) condition. The gene sets that were more strongly 
enriched in the cell death–predominant R-line (M249 DDR5) 
off MAPKi for 6 hours or 24 hours are shown in Fig. 2A. As 
expected, gene sets induced by MAPK hyperactivation were 
preferentially enriched in the cell death–predominant R-line 
(M249 DDR5) off double-drugs. Several gene sets induced 
by DNA damage were also preferentially enriched in M249 
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Figure 2.  Excessive ERK activation induces DNA damage and AIF-mediated death in the cell death–predominant MAPKi-addiction phenotype. A, Heat 
map showing the gene set variance analysis scores of differentially enriched gene signatures [median log fold change (FC) ≥ 1.25 in the off-drug condition 
compared with the on-drug condition in either cell line; additionally, differential enrichment between the cell death–predominant and slow cycling–pre-
dominant R-lines must also be higher (by at least 25%) in the off-drug condition than in the on-drug condition]. Yellow circles, MAPK hyperactivation 
gene sets; green circles, DNA damage gene sets. B and C, Levels of AIF, PARP, and pH2AX measured by Western blots (WB; B) or immunofluorescence (IF; C) 
in R-lines on or off MAPKi(s) for 1 and 3 (B) or 3 (C) days. For B, mitochondrial (Mito), nuclear (Nucl), cytoplasmic (Cyto) cellular fractions or whole-cell 
lysates (WCL). For C, nuclei visualized by DAPI; scale bars, 20 μm. D, DNA strand break measurements by the comet assay of R-lines on or off 
MAPKi(s) for 3 days. Tail length/moment FCs were quantified (n = 5; mean ± SDs). E, Temporal levels of pERK, pH2AX, and PARP in the nuclear fraction 
of R-cell lysates measured by WBs at indicated hours off MAPKi(s). Histone H3, loading control. (continued on following page)
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Figure 2. (Continued) F and G, Levels of indicated proteins by WBs in the nuclear fraction (F, G) or WCL (F) of R-lines, on or off MAPKi(s), transduced 
with empty vector (V) or AIF (F) or H2AX (G) shRNA lentiviruses. H–M, Percentages of Annexin-V/PI-positive dead cells (H, I), (continued on next page)
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Figure 2. (Continued) CFSE dye dilution patterns (J, K), and viable cell counts (L, M) in R-lines on or off MAPKi(s) for 6 days, transduced with empty 
vector (Vector) or AIF (J, L) or H2AX (K, M) shRNA lentiviruses. For L, M, n = 6; mean ± SDs; ***, P < 0.001 based on ANOVA. N and O, Subcellular localization 
of PAR (N) or levels of PARG (O) by IF in R-lines. Nuclei visualized by DAPI; scale bars, 20 μm. P, PARG and pERK levels by WBs in the indicated fractions of 
M249 DDR5 or nuclear fractions of indicated additional R-lines. For WB, GAPDH, loading control.
DDR5 when withdrawn from MAPKi. Consistently, when we 
probed the levels of pH2AX, a marker of DNA damage and 
mediator of repair, only the cell death–predominant R-line, 
M249 DDR5, displayed pH2AX induction during MAPKi 
withdrawal (Fig. 2B and C).
We hypothesized that a strong pERK rebound might induce 
mitochondrial dysfunction and reactive oxygen species (ROS) 
and thereby DNA damage. Indeed, MAPKi withdrawal induced 
pronounced levels of mitochondrial ROS, swelling, and depo-
larization only in the cell death–predominant R-lines (Sup-
plementary Fig. S3). Pan-caspase inhibition did not rescue 
cell death–predominant R-lines from cell death or long-term 
growth inhibition induced by MAPKi withdrawal (Supplemen-
tary Fig. S4A and S4B). Consistently, MAPKi withdrawal failed 
to induce cleaved caspase-3 by measuring its activity or staining 
(Supplementary Fig. S4C and S4D). We then tested whether 
AIF, which becomes cleaved and activated by mitochondrial 
dysfunction or depolarization and nuclear-localized to induce 
cell death via necrosis or parthanatos (26), might play a role 
in the cell death–predominant MAPKi-addiction phenotype. 
Consistently, cleaved AIF accumulated in the nuclear frac-
tion of the cell death–predominant R-line M249 DDR5, but 
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not in the slow cycling–predominant R-line M229 DDR4, 
after MAPKi withdrawal, in conjunction with nuclear loss of 
PARP1, a binding partner of AIF and pH2AX (Fig. 2B and C). 
By using the comet assay, we corroborated increased DNA 
damage preferentially in the cell death–predominant phe-
notype (Fig. 2D). In fact, when a slow cycling–predominant 
R-line (M229 DDR4) was engineered with BRAFV600E over-
expression, it then displayed increased DNA damage after 
MAPKi withdrawal, consistent with transition to a cell death–
predominant MAPKi-addiction phenotype (Fig. 2D). Fur-
thermore, pERK rebound coincided temporally with pH2AX 
induction in cell death–predominant R-lines (Fig.  2E). By 
manipulating the levels of pERK rebound pharmacologi-
cally, we showed that the extent of pERK rebound among cell 
death–predominant R-lines was strictly associated with the 
degree of DNA damage, as measured by the comet assay or 
levels of pH2AX, or with the level of clonogenic growth (Sup-
plementary Fig. S5A–S5E). In fact, pERK and pH2AX levels, 
quantified by immunofluorescence detection, across all cell 
death–predominant lines and tumors (see below) were highly 
correlated (Supplementary Fig. S5F).
To assess the functional contributions of AIF or H2AX 
to the cell death–predominant drug-addiction phenotype, we 
engineered M249 DDR5 and M245 SDR4 to express shVec-
tor, shAIF or shH2AX (Fig. 2F and G). Importantly, AIF or 
H2AX knockdown strongly diminished pH2AX accumula-
tion induced by MAPKi withdrawal and abrogated cell death 
while reducing cell-cycle deceleration and loss of viable cells 
(Fig. 2F–M). On the other hand, AIF knockdown did not 
rescue the growth-inhibitory effect of MAPKi withdrawal in 
slow cycling–predominant R-lines (Supplementary Fig. S6). 
Consistent with PAR as a key signal underlying excessive DNA 
damage-PARP-AIF-mediated parthanatos (a recently character-
ized variant of programmed cell death; ref. 26), we observed 
PAR cytoplasmic localization as well as loss of PARG, the major 
enzyme responsible for PAR catabolism, upon MAPKi with-
drawal only in the cell death–predominant R-line M249 DDR5, 
but not the slow cycling–predominant R-line SKMEL28 DDR1 
(Fig. 2N–P). Thus, nonapoptotic programmed cell death driven 
by excessive DNA damage underlies the cell death–predomi-
nant MAPKi-addiction phenotype.
Pharmacologic Induction of DNA Damage 
Promotes Death across All MAPKi-Resistant Cell 
Lines but Selectively during MAPKi Withdrawal
Because the prior results suggested a synthetic-lethal rela-
tionship between excessive pERK level/rebound and DNA 
damage in the cell death–predominant drug-addiction phe-
notype, we tested whether enhancing DNA damage via inhi-
bition of DNA damage repair in slow cycling–predominant 
R-lines would shift the drug-addiction phenotype toward 
cell death. We treated four slow cycling–predominant R-lines 
with ATMi, PARPi, or both after MAPKi withdrawal. In 
SKMEL28 DDR1, M229 DDR4, M238 DDR1, and M395 
DDR poly, ATMi + PARPi added upon BRAFi + MEKi with-
drawal strongly promoted pH2AX accumulation (Fig. 3A; 
Supplementary Fig. S7A), suppressed clonogenic growth or 
cell viability (Fig. 3B; Supplementary Fig. S7B and S7C), 
and induced cell death 6- to 10-fold (vs. only 2- to 4-fold 
on MAPKi; Fig. 3C; Supplementary S7D). To confirm the 
functional importance of DNA damage or its impaired repair 
in determining the cellular fate (death vs. slow-cycling) of 
R-lines off MAPKi or during pERK rebound, we knocked 
down BRCA1 in the slow cycling–predominant R-lines 
(Supplementary Fig. S7E) and determined the pH2AX lev-
els induced by MAPKi withdrawal, with or without PARPi 
(Fig. 3D). We found that downregulating DNA damage repair 
via BRCA1 knockdown and PARP1/2 inhibition, specifically 
after MAPKi withdrawal, strongly induced DNA damage 
(pH2AX levels), suppressed clonogenic growth (Fig.  3E) or 
cell viability (Supplementary Fig. S7F), and induced cell 
death 4- to 10-fold (vs. 0- to 3-fold on MAPKi; Fig. 3F).
We then assessed whether we could further enhance 
synthetic lethality in R-lines that were already cell-death 
predominant in their drug-addiction phenotype. In cell 
death–predominant R-lines (but not in a slow cycling–pre-
dominant R-line), PARPi + ATMi added upon MAPKi with-
drawal further induced the nuclear levels of AIF (Fig. 3G). 
Further boosting the induction of DNA damage (pH2AX 
levels) and nuclear AIF levels resulted in further clonogenic 
growth suppression that was evident after prolonged cul-
ture off MAPKi (Fig. 3H), consistent with the highest level 
of cell death detected (early during the course of culture) in 
cell death–predominant R-lines taken off MAPKi along with 
PARPi + ATMi cotreatment (Fig. 3I). As earlier data indicated 
that the cell death–predominant drug-addiction phenotype 
did not involve induction of caspase-3 activity and could not 
be reversed by a pan-caspase inhibitor (Supplementary Fig. 
S4A–S4D), we went further to test whether cell death induced 
by MAPKi withdrawal plus DNA-damage repair inhibition 
in slow cycling–predominant R-lines would upregulate cas-
pase-3 activity or function in a caspase-3–dependent manner 
(Fig. 3J; Supplementary Fig. S4E). As shown clearly, caspase-3 
was induced in slow cycling–predominant R-lines specifically 
during MAPKi withdrawal plus ATMi + PARPi cotreatment 
but not in a cell death–predominant R-line (Fig. 3K; Supple-
mentary Fig. S4E). Accordingly, in slow cycling–predominant 
R-lines off MAPKi and on ATMi + PARPi, a caspase-3 inhibi-
tor was able to rescue, at least partially, the drug-resistant 
melanoma cells from clonogenic suppression (Fig.  3L). In 
contrast, caspase-3 inhibition, consistent with pan-caspase 
inhibition (Supplementary Fig. S4A and S4B), failed to 
reverse the cell death–predominant phenotype (Fig. 3L).
Pharmacologically Augmenting ERK Rebound  
and DNA Damage Induces Tumor Regression  
of MEKi-Resistant NRASMUT or Atypical  
BRAFMUT Melanoma
Although MEKi monotherapy has been shown recently 
to have clinical activity against NRASMUT melanoma, resist-
ance developed readily (27). Thus, we sought a strategy 
that would exploit the aforementioned synthetic lethality 
to augment MEKi addiction in MEKi-resistant NRASMUT 
melanoma. Because type I RAF inhibitors, including vemu-
rafenib and dabrafenib, paradoxically activate ERK in the 
BRAFWT/NRASMUT context (19–22), we hypothesized that 
vemurafenib may augment MEKi withdrawal–induced pERK 
rebound and therefore a cell death–predominant drug-addic-
tion phenotype. To this end, we tested four NRASMUT mela-
noma cell lines (from three genetic backgrounds) resistant to 
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Figure 3.  Impairing DNA-damage repair augments MAPKi addiction. A, Western blot (WB) analysis of pH2AX levels in slow cycling–predominant 
R-lines on or off MAPKi(s), with or without ATMi and/or PARPi treatment for 3 days. B and C, Clonogenic growth (B) or percentages of Annexin-V/PI-
positive dead cells (C) in slow cycling–predominant R-lines on or off MAPKi(s) for 5 days, with or without ATMi and/or PARPi treatment.  D, WB analysis 
of BRCA1 and pH2AX levels in slow cycling–predominant R-lines, transduced with empty vector (V) or BRCA1-specific shRNA lentiviruses, on or off 
MAPKi(s), with or without PARPi treatment for 3 days. (continued on following page)
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Figure 3. (Continued)  E and F, R-line cells from D were subjected to the same assays as in B and C, respectively. For WBs, TUBULIN, loading control.  
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Figure 3. (Continued) G, Levels of indicated proteins by WBs in mitochondrial (MITO), nuclear (NUCL) subcellular fractions or whole-cell lysates (WCL) 
of slow cycling– versus cell death–predominant R-lines, on or off MAPKi(s), with or without ATMi and PARPi treatment for 3 days. HSP60, mitochondrial 
fraction control; Histone H3, nuclear fraction control. H and I, Clonogenic growth (H) or percentages of Annexin-V/PI-positive dead cells (I) in cell death–
predominant R-lines on or off MAPKi(s) for 6 days and 16 days (only in H), with or without ATMi and/or PARPi treatment.  (continued on following page)
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MEKi, which displayed variable degrees of ERK reactivation 
(on drug) or hyperactivation (off drug; Fig. 4A). Importantly, 
initiating BRAFi treatment at the time of MEKi withdrawal 
in these NRASMUT melanoma SDR clones resulted in a more 
rapid and robust pERK rebound, growth suppression, and cell 
death, compared with MEKi withdrawal alone (Fig. 4B–D). 
As was shown with cell death–predominant BRAFMUT DDR-
lines, MEKi withdrawal with or without BRAFi treatment in 
these NRASMUT SDR-lines induced pH2AX accumulation and 
altered PAR and AIF localization (Fig. 4E).
We also tested in vivo the synthetic-lethal relationship 
(between supraphysiologic ERK activity and excessive DNA 
damage) underlying a cell death–predominant drug-addic-
tion phenotype. We focused on a MEKi-resistant NRASMUT 
PDX model (Fig. 5A–E) and a MEKi-resistant non-BRAF 
V600 or atypical BRAF-mutant (BRAFS365L) PDX model 
(Fig. 5F–J), because targeted therapies against these mela-
noma genotypes are currently lacking. To derive a MEKi-
resistant NRASMUT PDX model, F1 PDX fragments were 
transplanted in NSG mice, and mice with tumors of similar 
volume were treated with trametinib at 5 mg/kg daily (day 
25), which led to maximal tumor regression within 10 days 
(day 33) followed by acquired MEKi resistance (Fig. 5A). One 
resistant tumor, excised at day 85, was fragmented and seri-
ally transplanted into mice with continuous daily MEKi treat-
ment until a cohort of mice with similar tumor volumes was 
assembled. This group of mice was divided into three sub-
groups: continuous trametinib, trametinib withdrawal, and 
vemurafenib treatment with trametinib withdrawal (Fig. 5B). 
Importantly, withdrawing trametinib (half-life of 4 hours) led 
to a transient tumor regression. However, vemurafenib treat-
ment upon trametinib withdrawal led to a significantly more 
sustained tumor regression (Fig. 5B–D). Analysis of these 
three groups of tumors revealed that, whereas trametinib 
withdrawal induced pERK, vemurafenib treatment on 
top of trametinib withdrawal further upregulated pERK 
(Fig. 5E). Consistent with cell line findings (Fig. 4), trametinib 
withdrawal, especially with vemurafenib treatment, induced 
DNA damage or pH2AX (Fig. 5E). Interestingly, trametinib 
withdrawal plus vemurafenib treatment led to redistribu-
tion of nuclear PAR to the cytoplasm (Fig. 5E). Consistent 
with tumor volumes/sizes/weights, tumors withdrawn from 
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Figure 3. (Continued)  J–L, Levels of caspase-3 activity (J, K) or clonogenic growth (L) with indicated MAPKi(s) treatment, with or without ATMi and 
PARPi, with or without caspase-3 inhibitor, Z-DEVD-FMK (20 μmol/L), in slow cycling–predominant R-lines (J) for 3 or 6 days, or cell death–predominant 
R-lines (K) for 3 days. For J, K, n = 5; mean ± SDs; *, P < 0.05; **, P < 0.01; ***, P < 0.001 based on ANOVA. Staurosporine (1 μmol/L) used to induce caspase-3 
activity and death.
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Figure 4. (Continued)  E, Levels and/or subcellular localization of pH2AX, PAR, and AIF in cell death–predominant MEKi-addicted R-lines on or off 
MEKi for 3 days, with or without BRAFi (5 μmol/L) treatment.
trametinib and then treated with vemurafenib displayed the 
lowest proliferation or Ki67 level (Fig. 5E). To derive a MEKi-
resistant atypical BRAFMUT PDX model, we treated F1 PDX 
BRAFS365L melanoma tumors in NSG mice with trametinib at 
5 mg/kg daily (day 25), which led to maximal tumor regres-
sion within 20 days (day 45) followed by acquired MEKi resist-
ance (Fig. 5F). The fastest growing MEKi-resistant tumor was 
selected for serial transplantation on continuous MEKi ther-
apy and divided into three experimental groups: continuous 
trametinib, trametinib withdrawal, and vemurafenib treat-
ment with trametinib withdrawal. As with MEKi-resistant 
NRASMUT PDX tumors, BRAF S365L PDX tumors resistant to 
MEKi responded to MEKi withdrawal but more robustly 
when a type I RAF inhibitor (vemurafenib) was added during 
MEKi withdrawal (Fig. 5G–I). Consistent with the notions 
that non-V600E BRAF mutants operate as RAF dimers and 
that enhanced RAF dimerization can drive MAPK reactivation 
and hence acquired MEKi resistance (18), we observed that 
BRAFi addition during MEKi withdrawal robustly upregu-
lated the pERK level (along with levels of pH2AX, PAR) coin-
cident with Ki67 downregulation (Fig. 5J and Supplementary 
Fig. S8A).
We then tested whether we could effect deeper and more 
sustained tumor regression by triggering DNA damage dur-
ing pERK rebound (Fig. 5K). We noticed in vitro (in  NRASMUT 
SDR-lines) that PARPi treatment alone (without ATMi) could 
enhance to some extent clonogenic suppression and cell 
death induced by MEKi withdrawal (Fig. 3H and I). Simi-
larly, in long-term clonogenic assays (Supplementary Fig. 
S8B), although BRAFi or PARPi each could further suppress 
the growth of NRASMUT SDR-lines withdrawn from MEKi, 
their combination led to the most profound suppression 
of growth. Importantly, in vivo, MEKi withdrawal combined 
with BRAFi + PARPi led to the most profound and sustained 
regression of MEKi-resistant NRASMUT melanoma (Fig. 5K 
and L), which was associated with the strongest induction 
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of pERK, pH2AX, and PAR and suppression of Ki67 (Sup-
plementary Fig. S8C and S8D). These and additional results 
(Supplementary Fig. S8E and S8F) suggest that inhibition of 
PARP specifically (or DNA damage repair in general) may be 
a potential strategy to augment MAPKi addiction.
We also assessed whether the synthetic lethality (between 
supraphysiologic levels of activated ERK and DNA damage) 
observed across MAPKi-resistant human melanoma cell lines 
and PDX tumors could also be observed in an immune-
competent context. To do this, we generated a syngeneic and 
transplantable model of MEKi-resistant NrasMUT melanoma. 
First, we derived a NrasQ61R/Ink4a/Lkb1 murine melanoma 
cell line (TpLN61R for Tyrosinase p16 Lkb1 NrasQ61R) from 
a tumor of the Tyr-CRE-NRAS Q61R genetically engineered 
murine melanoma model (28) and adapted TpLN61R to effi-
cient in vivo subcutaneous growth in C57BL/6 mice. These 
tumors were then chronically treated with trametinib at 
5 mg/kg daily until MEKi-resistant tumors arose (Fig. 6A). 
We then dissociated a resistant tumor and cultured the 
tumor cells with trametinib in vitro (up to 0.1 μmol/L over 
three weeks). In vitro, this MEKi-resistant cell line, termed 
NILR2R (Nras, Ink4a, Lkb1, Resistant mouse 2 Right flank), 
displayed robust time-dependent induction of pERK lev-
els by MEKi withdrawal, which was accelerated by BRAFi 
treatment (Fig. 6B). Consistent with robust pERK rebound 
levels, pH2AX was induced by MEKi withdrawal and fur-
ther induced by BRAFi treatment during MEKi withdrawal 
(Fig. 6C). Importantly, PARPi treatment (at a low concentra-
tion effective in augmenting cell killing among cell death–
predominant R-lines, Fig. 3) during MEKi withdrawal and 
BRAFi treatment resulted in even greater pH2AX accumula-
tion (Fig. 6C). Consistently, although BRAFi and/or PARPi 
had no appreciable effects on clonogenic growth or cell death 
levels of NILR2R in the presence of MEKi, BRAFi or PARPi 
treatment during MEKi withdrawal reduced clonogenic 
growth and increased the levels of cell death (Fig. 6D and E). 
Cotreatment of BRAFi and PARPi during MEKi withdrawal 
further reduced growth and increased death (Fig. 6D and E). 
Consistent with a cell death–predominant drug-addiction 
phenotype observed among MAPKi-resistant human mela-
noma cell lines and PDX tumors, this MEKi-resistant murine 
melanoma cell line also displayed upregulation of PAR levels 
and nuclear localization of AIF during induction of the 
drug-addiction phenotype (Fig. 6F). Finally, we reimplanted 
NILR2R back into C57BL/6 mice treated with trametinib 
(5 mg/kg via daily gavage) and identified five groups of 
mice with closely matched tumor volumes (Fig. 6G). We 
then tested the individual tumor-shrinkage effect of BRAFi 
or the combined effect of BRAFi + PARPi treatments in 
vivo. As expected based on prior results, PARPi intraperito-
neal treatments had no significant effect on the growth of 
NILR2R tumors on continuous MEKi oral treatments. MEKi 
discontinuation alone led to transient tumor shrinkage. 
Importantly, BRAFi oral treatment beginning with MEKi dis-
continuation prolonged the tumor-shrinkage effect of MEKi 
withdrawal (Fig. 6 G–I). PARPi + BRAFi cotreatment during 
MEKi withdrawal led to the most sustained tumor regression 
(Fig. 6G). Thus, pharmacologically augmenting ERK rebound 
and DNA damage to maximize regression of MEKi-resistant 
NrasMUT melanoma tumors during MEKi withdrawal may be 
feasible in an immune competent host.
DISCUSSION
Understanding the mechanisms underlying the cancer 
vulnerability of MAPKi addiction availed us with poten-
tial therapeutic opportunities (Fig. 7). During a predomi-
nantly tumor cell–death rather than cell-cycle deceleration 
response upon drug withdrawal, MAPKi-resistant mela-
noma, regardless of the specific underlying driver(s) of 
resistance, displays a synthetic lethality between acute, 
suprabasal ERK hyperactivation and excessive DNA damage. 
Death by this synthetic lethality in the context of a robust 
pERK rebound is characterized by AIF-dependent but cas-
pase-3–independent death. Impairing DNA-damage repair 
pharmacologically, on top of DNA damage already induced 
by strong pERK rebounds, further boosted AIF-dependent 
death of MAPKi-resistant melanoma cells. On the other 
hand, a weak MAPKi withdrawal–induced pERK rebound 
was sufficient to elicit only a cell-cycle slowdown, leading 
to persisters that will resume rapid proliferation. However, 
upon MAPKi withdrawal, an innately weak pERK rebound 
coupled with impairment of the DNA-damage repair 
machinery turned a predominantly slow-cycling response 
to a cell-death response that was caspase-3–dependent. 
Based on these findings, one would expect an even stronger 
synthetic lethality for drug-withdrawn, MAPKi-resistant 
melanoma harboring genetic loss of BRCA1/2 or display-
ing BRCAness (ref. 29; either preexisting or acquired during 
MAPKi therapy). Thus, after emergence of MAPKi-resistant 
clones, targeting the DNA-damage repair pathways subse-
quent to cessation of MAPKi dosing may specifically select 
against disease progression across the spectrum of MAPKi-
addiction phenotypes.
In the particular contexts of MEKi-resistant NRASMUT mel-
anoma, type I RAF inhibitors such as vemurafenib further 
augmented ERK rebound (on top of what was induced by 
MEKi withdrawal) and cell death. Counter to the dogma that 
type I RAF inhibitor is contraindicated for NRASMUT mela-
noma, its ability to boost ERK levels in the context of MEKi 
Figure 5.  Excessive ERK and DNA damage induce regression of MEKi-resistant PDX tumors. A, Tumor volumes (mean ± SEM) of a NRASMUT PDX 
transplanted in NSG mice in response to daily gavage with the vehicle (n = 3) or trametinib (5 mg/kg; n = 5). B, R1 trametinib-resistant NRASMUT PDX 
tumors were grown in NSG mice for 55 days with daily trametinib (5 mg/kg) gavage until initiating indicated daily treatments or regimens (n = 4 in each 
group). Tumor volumes are shown as means ± SEM. P values, Student t test. MEKi, trametinib (5 mg/kg); BRAFi, vemurafenib (100 mg/kg). C, Pictures of 
tumors from three experimental groups in B on day 63. D, Tumor weights (means ± SEM; P value, unpaired t test) of three experimental groups in B. E, 
Levels of indicated proteins in representative tissue sections of tumors in C. Scale bars, 20 μm. F–J, As in A to E except experiments used a distinct PDX 
model harboring BRAFS365L and individual tumor growth curves were plotted separately in F. The MEKi-resistant tumor (R3) which arose first was frag-
mented, serially passaged, and used in G. K and L, R1 trametinib-resistant NRASMUT PDX tumors were serially passaged in NSG mice with daily trametinib 
(5 mg/kg) gavage until segregation into seven groups (1, 2, 3, 5, n = 3 per group; 4, 6, 7, n = 5 per group). Tumor volumes and weights are shown as means  
± SEM. P values, Student t test.
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Figure 6.  BRAF and PARP inhibitors augment MEKi addiction of NrasMUT murine melanoma in an immune competent host. A, Tumor volumes (mean ±  
SEM) of TpLN61R murine melanoma cells transplanted in C57BL/6 mice in response to daily gavage with the vehicle (n = 6) or trametinib (5 mg/kg; n = 6). 
One resistant tumor on day 36 was dissociated and cultured as a MEKi-resistant cell line (NILR2R). B, Western blot levels of pERK, ERK, and the loading 
control GAPDH in the MEKi-resistant NrasMUT SDR-line NILR2R, with indicated hours off MEKi/trametinib (0.1 μmol/L) treatment, with or without BRAFi/
vemurafenib (1 μmol/L) treatment. C, Analysis of NILR2R protein lysates by Western blots of pERK and pH2AX levels on or off MEKi, with or without 
BRAFi (1μmol/L) and/or PARPi (0.2 μmol/L) treatment for 3 days. D and E, Clonogenic growth (D; 8 days) and percentages of Annexin-V/PI-positive dead 
cells (E; 5 days) in NILR2R, on or off MEKi/trametinib (0.1 μmol/L), with or without BRAFi/vemurafenib (1 μmol/L) and/or PARPi (0.2 μmol/L) treat-
ments. For D, cultures were seeded at 30K cells per well, except for the third row where cultures were seeded at 150K cells per well. F, Levels and/or 
subcellular localization of pH2AX, PAR, and AIF in NILR2R, on or off MEKi for 3 days, with or without BRAFi and/or PARPi treatment. Scale bars, 20 μm. 
G, Trametinib-resistant NILR2R cells were transplanted subcutaneously in C57BL/6 mice with daily trametinib (5 mg/kg) gavage until segregation into 
five groups (n = 6 per group). Tumor volumes are shown as means ± SEM. P values, Student t test. H, Pictures of tumors from the first four experimental 
groups (mice sacrificed due to tumor ulceration) in G on day 26. I, Tumor weights (means ± SEM; P value, unpaired two-way t test) of the first four experi-
mental groups in G.
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addiction suggests a novel context-dependent  application. 
Furthermore, MEKi-resistant melanoma with atypical 
BRAFMUT mutations likely upregulated RAF dimer levels (as 
a mechanism of resistance). This may explain the ability of 
vemurafenib to enhance pERK induction and tumor regres-
sion during MEKi withdrawal. Given the potential liability of 
prolonged BRAFi treatment in these genetic contexts, further 
studies are required to define an optimal BRAFi treatment 
duration in the context of augmenting drug addiction.
This study highlights the potential utility of capitalizing 
on MAPKi-addiction mechanisms to control MAPKi-resistant 
subclones even before the development of clinically evident 
disease progression. Our recent study identified melanoma 
tumors, during MAPKi-induced regression, to be undergoing 
dynamic and stereotypic tumor cell and immune compart-
mental adaptations (30). It will also be important to char-
acterize the immune infiltration/composition and identify 
specific adaptive immune resistance mechanisms associated 
with tumor regression resulting from a pharmacologically 
augmented drug-addiction phenotype. Furthermore, MAPK 
inhibitors with ideal clinical pharmacokinetic properties 
(short half-lives, e.g., encorafenib, binimetinib) may be par-
ticularly useful for implementation of strategies based on 
MAPKi addiction in human subjects. Finally, understanding 
in further detail how excessive ERK and DNA damage levels 
engage distinct programmed cell death pathways promises to 
guide the development of rotational therapies that adapt to 
evolving cancer vulnerabilities.
METHODS
Cell Culture, Subline Derivation, Constructs, and Inhibitors
All cell lines were routinely tested for Mycoplasma, and cell line and sub-
line identities have been ensured by the GenePrint 10 system (Promega) at 
routine intervals during the course of this study for banking and experi-
mental studies. All cell lines were maintained in DMEM high glucose with 
10% heat-inactivated FBS (Omega Scientific) and 2 mmol/L glutamine in 
a humidified, 5% CO2 incubator. All M series cell lines were established 
from patient-derived tumors at the University of California, Los Angeles 
(UCLA). The TpLN61R cell line was derived at the University of North 
Carolina and adapted to in vivo growth at UCLA in 2016. The NILR2R 
cell line was established in vitro from a MEKi-resistant tumor at UCLA 
in 2017. SKMEL28 was obtained from Dr. Alan Houghton (between 
2008 and 2010). To derive resistant clones, parental melanoma cells 
seeded at low density were treated with BRAFi + MEKi (vemurafenib + 
selumetinib; BRAFMUT) or MEKi (trametinib; NRASMUT) every 2 to 3 days 
for 6 to 12 weeks, and proliferative colonies were ring-isolated (except 
those designated “poly” for polyclonal where ring cloning was not per-
formed) and expanded. shH2AX, shFRA1, shJUNB, and vector (pLKO.1) 
were obtained commercially (ThermoFisher). shBRCA1 and vector 
(pGIPZ) were accessed through the Molecular Screening Shared Resource 
at UCLA. BRAFV600E was subcloned into the doxycycline-repressible len-
tiviral vector pLVX-Tight-Puro ( ClontechLaboratories). Overexpression 
and knockdown constructs were packaged into lentiviral particles for 
infection. Inhibitors were obtained from the following: vemurafenib in 
vitro (Plexxikon); vemurafenib in vivo, selumetinib in vitro, trametinib 
in vitro and in vivo (LC Laboratories); ERKi/SCH772984 (Merck); p38i/
SB203580, PARPi/Olaparib, ATMi/KU-55933, and caspasei/Z-VAD-
FMK (Selleckchem).
Protein Detection
Cells were lysed in RIPA buffer (Sigma) with protease inhibitor (Roche) 
and phosphatase inhibitor (Santa Cruz Biotechnology) cocktails for 
Western blotting. For immunohistochemistry (IHC), tissues were fixed 
either in 4% paraformaldehyde (PFA) and sucrose cryoprotected in OCT 
or in formalin and embedded in paraffin (FFPE). For FFPE tissues, after 
deparaffinization and rehydration, tissue sections were subjected heat 
for antigen retrieval. PFA/OCT sections were not subjected to antigen 
retrieval. Both IHC and immunocytochemistry of cell lines were per-
formed with Alexa Fluor–conjugated secondary antibodies (Life Tech-
nologies) on 4% PFA-fixed cells. Nuclei were counterstained by DAPI. 
Fluorophore signals were captured with a Zeiss microscope (AXIO 
Imager A1) mounted with a charge-coupled device camera (Retiga EXi 
QImaging), and the images captured by Image-pro plus 6.0. Western 
blots and immunofluorescence assays were performed using the follow-
ing antibodies: pERK1/2 (T202/Y204), p-c-FOS (S32), pFRA1 (S265), 
p-p38 MAPK (T180/Y182), p-HSP27 (S82), pHistone H2A.X (S139), 
total ERK1/2, c-FOS, FRA1, FOSB, p21, AIF, PARG, BRCA1, GAPDH 
(Cell Signaling Technology), TUBULIN (Sigma), PARP1, BRAF (Santa 
Cruz Biotechnology), PAR (Enzo), and Ki67 (EMD Millipore). Western 
blot quantification was performed using NIH ImageJ.
Cell Line–Based Assays
Clonogenic assays were performed by plating cells at single-cell 
density in six-well plates, and inhibitor/media replenished every 
2 days for 7 days, unless noted otherwise. Colonies were fixed in 4% 
paraformaldehyde and stained with 0.05% crystal violet. Viable cell 
Figure 7.  Strategies to select against MAPKi-resistant melanoma. Schematic showing MAPKi-addiction phenotypes being driven by pERK rebound 
levels and potential therapeutic strategies (enhancing pERK or impairing DNA-damage repair) that promote tumor cell death (apoptosis or parthanatos) 
or regression.
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counts were performed in triplicate wells (in six-well plates). Cell 
death assays were performed by plating indicated cell lines with or 
without MAPKi(s) for 6 days (unless otherwise indicated), and cells 
were stained with Annexin V–FITC and propidium iodide for 15 min-
utes at room temperature before sample loading (LSR II Flow Cytom-
etry, BD Bioscience). CFSE (Molecular Probes) dilution detected by 
flow cytometry was used to monitor cell division. Cells were loaded 
with 3 μmol/L of CFSE and cultured for 6 days. Samples were col-
lected and fixed in 2% PFA and analyzed with LSRII. Flow cytometry 
data were analyzed by FlowJo. Senescence was assessed by a Senes-
cence Associated β-Galactosidase staining kit (Cell Signaling Tech-
nology) with MAPKi withdrawn for 6 days. For vital imaging, cells 
were plated onto gridded dishes (Sigma) and imaged at indicated 
time points at predesignated areas. Comet assays (Cell Biolabs, Inc.) 
were performed by plating cell lines in six-well plates in the presence 
or absence of MAPKi for 3 days. Stranded breaks were detected by 
following the manufacturer’s recommendations, imaged with a Zeiss 
microscope (AXIO Imager A1), and distance of tails measured with 
Image-pro plus 6.0. Caspase-3 activity was assessed using Caspase-
Glo 3/7 kit (Promega) by plating cells in white-walled, 96-well plates 
in the presence or absence of indicated inhibitors for 3 or 6 days.
RNA-seq Analysis
RNA-seq data from cell lines were generated using 2 × 100 bp paired-
end sequencing using the Illumina HiSeq2000 platform. Paired-end 
reads were mapped to the UCSC hg19 reference genome using Tophat2 
(31). Normalized expression levels of genes were expressed in FPKM 
values as generated by cuffquant and cuffnorm. Both programs were 
run with the option “–frag-bias-correct” and “–multi-read-correct” to 
improve sensitivity. For differential gene expression calls, a gene was 
defined as differentially expressed when its expression increased or 
decreased by at least 2-fold. RNA-seq runs on multiple sequencing 
lanes were independently mapped, and the expression values of each 
gene (in FPKM) were averaged across multiple lanes. To overcome 
noise in differential expression values caused by extremely low FPKM 
levels, we added a pseudo-FPKM value of 0.1 to all expression values. 
RNA-seq data have been made available through the Gene Expression 
Omnibus (GEO) at the accession number GSE87326.
Transcription Factor Enrichment Analysis
We collected transcription factor (TF) binding motifs in the form 
of position weight matrices (PWM) from the JASPAR database (32). 
Instead of using a fixed PWM score cutoff(s) as done in other PWM 
matching programs, we estimated the significance of the PWM score in 
a gene’s promoter, which is defined as −1,500 to +1,500 bp from tran-
scription start site (TSS), by comparing the score with a background 
distribution of the same PWM’s scores on nonpromoter regions from 
randomly selected genes. Specifically, we collected 10,000 random 3 KB 
intragenic regions (excluding the genes’ promoter regions) and, for each 
sequence, computed the best score of a PWM. These scores defined an 
empirical background distribution of the PWM, and we defined a sig-
nificant match of the PWM if and only if (i) the PWM score was greater 
than or equal to the 95th percentile of the background PWM scores (i.e., 
P ≤ 0.05) and (ii) a PWM score was at least 0.75. This approach avoided 
applying the same absolute PWM score cutoff on PWMs with differing 
lengths and complexities. To estimate enrichment of a TF’s PWM W in 
a set of coregulated genes G, we compared the number of significant 
matches of W in the promoter regions in G (accounting for possible 
multiple TSS for each gene) and the number of matches against a set of 
randomly selected promoter regions of the same size. We repeated the 
latter step 100,000 times to estimate the empirical enrichment P value 
of the PWM. Finally, we corrected the PWM enrichment P values across 
all tested PWMs for multiple hypothesis testing using the Benjamini–
Hochberg (FDR) method. A TF’s PWM was defined as enriched in a set 
of genes when its adjusted enrichment P value was ≤ 0.05.
Gene Set Enrichment Analysis
Paired gene set enrichment analyses between off- versus on-drug 
conditions or between two different cell lines were performed as 
described previously (1). We computed differential gene set enrich-
ments of the gene sets in the C2 CGP, C6, and Hallmark subsets from 
the Molecular Signature Database of the Broad Institute using the 
following steps: (i) We calculated log2 fold changes (log2 FC) of mRNA 
expression of each gene in M249 DDR5 compared with SKMEL28 
DDR1 at all three treatment conditions, i.e., on-drug 6 hours, off-
drug 6 and 24 hours; (ii) Based on the log2 FC values, we computed 
the differential enrichment of each gene set between M249 DDR5 and 
SKMEL28 DDR1 in all three treatment conditions (cutoff for differ-
ential enrichment, Wilcoxon rank-sum test between genes within the 
gene set and the rest of the genes; P ≤ 0.05; median of up-expression 
across all genes in the gene set ≥ 25%, i.e., median log2 FC ≥ 0.322); 
(iii) To exclude differential enrichment already present between on-
drug condition, for each of the gene sets meeting the cutoffs in step 2, 
we required that the difference between the median log2 FC in either 
off-drug condition to be higher than the median log2 FC in the on-
drug condition by at least 0.322 (1.25-fold higher); and (iv) For visuali-
zation, we computed the single sample enrichment GSVA scores (33) 
of the selected gene sets from step 3 using log2 CPM values as input.
PDX Models and Murine Melanoma
Mouse experiments were approved by the Animal Research Com-
mittee at UCLA. Tumor fragments derived from a NRASQ61R and a 
BRAFS365L metastatic melanoma (F0), which were obtained from 
two distinct patients with approval by the local Institutional Review 
Board, were transplanted subcutaneously in sex-matched NSG mice 
(6–8 weeks old). Tumors were measured with a caliper every 2 days, and 
tumor volumes were calculated using the formula (length × width2)/2. 
Trametinib-resistant tumors were cut into fragments, which were 
serially transplanted. NILR2R cells were injected at 1 million 
cells per flank in C57BL/6 mice. Mice were treated with vehicle (0.5% 
HPMC–0.2% Tween 80, pH8), trametinib (5 mg/kg), or vemurafenib 
(100 mg/kg) by oral gavage daily, or olaparib (25 or 50 mg/kg) by daily 
i.p. injections.
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